Abstract: One embodiment provides a tungsten wire containing 1 to 10% by mass of rhenium, the wire having a point indicating a 2% elongation within a quadrangle formed by joining points with straight lines, where the values of x and y are point (20, 75), point (20, 87), point (90, 75), and point (90, 58), in this order; wherein the wire diameter of the tungsten wire is represented by x ?m, and the elongation of the tungsten wire is 2% after electrically heating with an electrical current which is a ratio of y % to the fusion current (FC) at the wire diameter x ?m, and wherein a semi-logarithmic system of coordinates is expressed by a horizontal axis using a logarithmic scale of the wire diameter x and a vertical axis using a normal scale of ratio y to the fusion current.

Abstract: According to one embodiment, a tungsten alloy includes 0.1 to 5 wt % of Zr in terms of ZrC.

Abstract: In one embodiment, a hydrophilic member includes a substrate having a surface and particles existing at least on the surface of the substrate. The particles are constituted of at least one selected from tungsten oxide particles and tungsten oxide composite particles. The substrate surface on which the particles exist has an arithmetic mean roughness Ra in the range of 1 nm to 1000 nm with a reference length of 100 ?m, and exhibits hydrophilicity independently of light.

Abstract: According to one embodiment, a tungsten alloy includes a W component and a Hf component including HfC. A content of the Hf component in terms of HfC is 0.1 wt % or more and 3 wt % or less.

Abstract: In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=log C?log A], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 lx. for 24 hours.

Abstract: An aqueous dispersion of an embodiment includes visible-light responsive photocatalytic composite microparticles containing tungsten oxide and zirconium oxide, and an aqueous dispersion medium in which the photocatalytic composite microparticles are dispersed. In the photocatalytic composite microparticles, a ratio of a mass of the zirconium oxide to a mass of the tungsten oxide is in a range of from 0.05% to 200%, and a D50 particle size in particle size distribution is in a range of from 20 nm to 10 ?m. The aqueous dispersion has pH in a range of from 1 to 9.

Abstract: In one embodiment, an aqueous dispersion liquid contains at least one particles selected from tungsten oxide particles and tungsten oxide composite particles. A mean primary particle diameter (D50) of the particles is in the range of 1 nm to 400 nm. In the aqueous dispersion liquid, concentration of the particles is in the range of 0.1 mass % to 40 mass %, and pH is in the range of 1.5 to 6.5. The aqueous dispersion liquid excels in dispersibility of particles and capable of maintaining good liquidity for a long period.

Abstract: A cation adsorbent of an embodiment includes tungsten oxide particles having a BET specific surface area in a range of 0.82 m2/g or more and 820 m2/g or less. The cation adsorbent is added to a solution to be treated containing cations being recovery objects, and the cation adsorbent adsorbing the catious is precipitated. The generated precipitate is separated from the solution to recover the cations.

Abstract: In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=log C?log A], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours.

Abstract: In one embodiment, an aqueous dispersion liquid contains at least one particles selected from tungsten oxide particles and tungsten oxide composite particles. A mean primary particle diameter (D50) of the particles is in the range of 1 nm to 400 nm. In the aqueous dispersion liquid, concentration of the particles is in the range of 0.1 mass % to 40 mass %, and pH is in the range of 1.5 to 6.5. The aqueous dispersion liquid excels in dispersibility of particles and capable of maintaining good liquidity for a long period.

Abstract: An object of the invention is to provide a photocatalyst material having a higher catalyst effect than conventional photocatalyst materials. The photocatalyst material of the invention contains, as its major component, a tungsten oxide powder excited by a light source which emits light having a wavelength of 430 to 500 nm, the photocatalyst material having a decomposition ability of 50% or more wherein the decomposition ability is given by the following equation based on the following test: [Test for decomposition ability]: 1 g of a tungsten oxide powder and 20 ppm of acetaldehyde (amount A) are poured into a 3-liter glass container, and acetaldehyde (amount B) is measured after light having a peak wavelength of 460 nm±10 nm is irradiated to the mixture for 2 hours to measure the decomposition ability (%): Decomposition ability (%)=[(acetaldehyde amount A?acetaldehyde amount B)/acetaldehyde amount A]×100.

Abstract: In one embodiment, an aqueous dispersion liquid contains at least one particles selected from tungsten oxide particles and tungsten oxide composite particles. A mean primary particle diameter (D50) of the particles is in the range of 1 nm to 400 nm. In the aqueous dispersion liquid, concentration of the particles is in the range of 0.1 mass % to 40 mass %, and pH is in the range of 1.5 to 6.5. The aqueous dispersion liquid excels in dispersibility of particles and capable of maintaining good liquidity for a long period.

Abstract: One embodiment provides a tungsten wire containing 1 to 10% by mass of rhenium, the wire having a point indicating a 2% elongation within a quadrangle formed by joining points with straight lines, where the values of x and y are point (20, 75), point (20, 87), point (90, 75), and point (90, 58), in this order; wherein the wire diameter of the tungsten wire is represented by x ?m, and the elongation of the tungsten wire is 2% after electrically heating with an electrical current which is a ratio of y % to the fusion current (FC) at the wire diameter x ?m, and wherein a semi-logarithmic system of coordinates is expressed by a horizontal axis using a logarithmic scale of the wire diameter x and a vertical axis using a normal scale of ratio y to the fusion current.

Abstract: In one embodiment, an aqueous dispersion liquid contains at least one particles selected from tungsten oxide particles and tungsten oxide composite particles. A mean primary particle diameter (D50) of the particles is in the range of 1 nm to 400 nm. In the aqueous dispersion liquid, concentration of the particles is in the range of 0.1 mass % to 40 mass %, and pH is in the range of 1.5 to 6.5. The aqueous dispersion liquid excels in dispersibility of particles and capable of maintaining good liquidity for a long period.

Abstract: In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=logC?logA], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours.

Abstract: In one embodiment, a visible light responsive photocatalyst powder has organic gas decomposition performance that responds nonlinearly to an amount of irradiated light under visible light in an illuminance range of not less than 200 lx nor more than 2500 lx. The visible light responsive photocatalyst powder has a gas decomposition rate of 20% or more, for example, when visible light having only a wavelength of not less than 380 nm and an illuminance of 2500 lx is irradiated, the gas decomposition rate (%) being set as a value calculated based on [formula: (A?B)/A×100], where A represents a gas concentration before light irradiation and B represents a gas concentration when not less than 15 minutes have elapsed from the light irradiation and, at the same time, the gas concentration is stable, the gas concentrations being measured while allowing an acetaldehyde gas having an initial concentration of 10 ppm to flow into a flow-type apparatus in which 0.2 g of a sample is placed.

Abstract: According to one embodiment, a photocatalyst body satisfies at least one condition described below, (1) a ratio of an absorption intensity at a wave number of 3450 cm?1 to a peak intensity of an absorption at about 1037 cm?1 being 2.5 or less in an analysis of a surface of the body, (2) a ratio of a maximum peak intensity of an absorption in a wave number range of not less than 1500 cm?1 and not more than 1700 cm?1 to a peak intensity of an absorption at about 1037 cm?1 being 0.7 or less in the analysis and (3) the photocatalyst body having no absorption peak in a wave number range of not less than 5000 cm?1 and not more than 5400 cm?1 or a ratio of a maximum peak intensity of an absorption to an absorption intensity at 5250 cm?1 being 1.7 or less in the analysis.

Abstract: In one embodiment, an aqueous dispersion liquid contains at least one particles selected from tungsten oxide particles and tungsten oxide composite particles. A mean primary particle diameter (D50) of the particles is in the range of 1 nm to 400 nm. In the aqueous dispersion liquid, concentration of the particles is in the range of 0.1 mass % to 40 mass %, and pH is in the range of 1.5 to 6.5. The aqueous dispersion liquid excels in dispersibility of particles and capable of maintaining good liquidity for a long period.

Abstract: In one embodiment, a hydrophilic member includes a substrate having a surface and particles existing at least on the surface of the substrate. The particles are constituted of at least one selected from tungsten oxide particles and tungsten oxide composite particles. The substrate surface on which the particles exist has an arithmetic mean roughness Ra in the range of 1 nm to 1000 nm with a reference length of 100 ?m, and exhibits hydrophilicity independently of light.

Abstract: A method for producing a tungsten trioxide powder for a photocatalyst according to the present invention is characterized by comprising a sublimation step for obtaining a tungsten trioxide powder by subliming a tungsten metal powder or a tungsten compound powder by using inductively coupled plasma process in an oxygen atmosphere, and a heat treatment step for heat-treating the tungsten trioxide powder obtained in the sublimation step at 300° C. to 1000° C. for 10 minutes to 2 hours in an oxidizing atmosphere. A tungsten trioxide powder which is obtained by the method for producing a tungsten trioxide powder for a photocatalyst according to the present invention has excellent photocatalytic performance under visible light.